HIFU PROSTATE website was set up to provide patients with useful information relating to prostate cancer treatments and particularly on HIFU treatment. The information displayed on HIFU PROSTATE website is targeted to the general public and to physicians seeking information on prostate cancer and HIFU technology.The information available on HIFU PROSTATE web site is not a substitute to professional diagnosis and to discussions with your physician and/or urologist.
Hifu Prostate is entirelly funding by EDAP TMS company. EDAP TMS is established at 4, rue du Dauphiné, 69120 Vaulx-en-Velin, France.
There is no advertising in Hifu Prostate web site.
Global leader in therapeutic ultrasound and present in the market for more than 40 years, EDAP TMS (NASDAQ: EDAP) develops, manufactures, promotes and distributes worldwide minimally-invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS just introduced the Focal One® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing Ablatherm® Robotic HIFU. As a pioneer and key player in the field of extracorporeal lithotripsy (ESWL), EDAP TMS exclusively utilized the latest generation of shock wave source in its Sonolith®range of ESWL systems. EDAP TMS is continuously focusing on delivering technologies that guarantee positive outcomes which are replicable, with low side effectsand preserve patients’ quality of life.
EDAP TMS develops its medical equipment with the support from the French National Institute for Health and Medical Research (Inserm), and the urology team at Edouard Herriot hospital in Lyon, France. Expert teams from these three organizations has been working together for many years, developing current and future medical treatments that meet surgeons’ needs and preserve at best patients’ quality of life.